Overview

A Phase 1b Study Assessing the PK, PD, Safety & Tolerability of SB414 in Atopic Dermatitis

Status:
Completed
Trial end date:
2018-05-11
Target enrollment:
Participant gender:
Summary
This is a Phase 1b, 2-week study assessing the pharmacokinetics, pharmacodynamics, safety and tolerability of SB414 in subjects with mild to moderate AD.
Phase:
Phase 1
Details
Lead Sponsor:
Novan, Inc.
Collaborator:
Novella Clinical